Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of IDRX-42 in metastatic and/or unresectable GIST
2024-514930-19-00Phase 2Authorised
- Sponsor
- IDRx
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of IDRX-42 in gastrointestinal stromal tumor (GIST), sponsored by IDRx. Primary endpoints: Treatment-emergent adverse events and dose-limiting toxicities (Phase 1), Safety in Phase 1b and 2 more. Planned start Aug 2024; status: authorised.
02
Drugs
IDRX-42
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2024-514930-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514930-19-00.